Sino Biopharmaceutical Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBHMY research report →
Companywww.sinobiopharm.com
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections.
- CEO
- S. Y. Tse
- IPO
- 2017
- Employees
- 24,379
- HQ
- Wan Chai, HK
Price Chart
Valuation
- Market Cap
- $12.74B
- P/E
- 35.07
- P/S
- 2.56
- P/B
- 2.68
- EV/EBITDA
- 12.44
- Div Yield
- 1.71%
Profitability
- Gross Margin
- 82.07%
- Op Margin
- 21.84%
- Net Margin
- 7.36%
- ROE
- 7.24%
- ROIC
- 8.99%
Growth & Income
- Revenue
- $30.97B · 7.28%
- Net Income
- $2.28B · -34.87%
- EPS
- $2.60 · -35.00%
- Op Income
- $6.63B
- FCF YoY
- 45.35%
Performance & Tape
- 52W High
- $20.16
- 52W Low
- $9.48
- 50D MA
- $15.24
- 200D MA
- $17.70
- Beta
- 0.64
- Avg Volume
- 5
Get TickerSpark's AI analysis on SBHMY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SBHMY Coverage
We haven't published any research on SBHMY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SBHMY Report →